Document is current
Any future updates will be listed below
-
Authors
Zaffran, Ilan
Gaur, Pratibha https://orcid.org/0000-0002-3155-5944
Ofori, Prince https://orcid.org/0000-0002-6885-1907
Charpak-Amikam, Yoav https://orcid.org/0000-0001-7625-0741
Pahima, Hadas
Shasha, David
Osherov, Nir https://orcid.org/0000-0002-0433-0096
Hube, Bernhard https://orcid.org/0000-0002-6028-0425
Ben-Ami, Ronen
Naglik, Julian R. https://orcid.org/0000-0002-8072-7917
Mandelboim, Ofer https://orcid.org/0000-0002-9354-1855
Vitte, Joana
Levi-Schaffer, Francesca https://orcid.org/0000-0003-0620-2810
-
Funding
Funding for this research was provided by:
Israel Science Foundation (442/18)
Wellcome Trust (214229_Z_18_Z)
- License Information
-
More Information
Article History
Received: 4 July 2023
Accepted: 15 September 2025
First Online: 21 October 2025
Competing interests
: J.V. reports speaker and consultancy fees and travel support in the past 5 years from Astra Zeneca, HpVac, Novartis, L’Oréal, Sanofi, Stallergènes-Greer, and Thermo Fisher Scientific. The other authors have no financial competing interests.
